NCT02268435撤回1 期
A Trial of Dovitinib in Combination With Imatinib in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors After Failure to Imatinib and Sunitinib
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 主要终点
- Maximal tolerated dose and recommended dose
研究概览
简要总结
The objective of this study is to determine the recommended dose of combination of dovitinib and imatinib in phase I study.
详细描述
combination of dovitinib and imatinib could lead to additive or synergistic effect in patients who had failure of standard TKI therapies including imatinib, sunitinib, and/or regorafenib. In this phase I-II study of dovitinib plus imatinib, we aim to determine a recommended dose of dovitinib plus imatinib and to evaluate the safety and activity of the combination at the recommended dose as a 3rd or more line of treatment in metastatic or unresectable GIST.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 19 years or older
- •Histologically confirmed metastatic or unresectable GIST with CD117(+), DOG-1(+), or mutation in KIT or PDGFRα gene
- •Disease control (response or stabilization for at least 6 months with first-line imatinib and failure of prior treatments for GIST, including at least both imatinib and sunitinib and/or regorafenib. However, patients with imatinib rechallenge will not be accrued.
- •ECOG performance status of 0~2
- •Resolution of all toxic effects of prior treatments to grade 0 or 1
- •At least one evaluable or measurable lesion for phase I study
- •Adequate bone marrow, hepatic, renal, and other organ functions
- •Neutrophil > 1,500/mm3
- •Platelet > 75,000/mm3
- •Hemoglobin > 8.0 g/dL
- •Total bilirubin < 1.5 x upper limit of normal
- •AST/ALT < 2.5 x ULN with no exceptions
- •Creatinine < 1.5 x ULN
- •Life expectancy > 12 weeks
- •Women with reproductive potential must have a negative serum or urine pregnancy test; and men and women of reproductive potential must practice an effective method of avoiding pregnancy while receiving study drug.
- •Washout period of previous TKIs or chemotherapy for more than 4 times the half life.
- •No prior use of dovitinib or other inhibitors of FGFR except regorafenib
- •Provision of a signed written informed consent
排除标准
- •Women of child-bearing potential who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control. Barrier contraceptives must be used throughout the trial in both sexes.
- •Clinically significant cardiac disease or impaired cardiac function or clinically significant cardiac diseases, including any one of the following:
- •LVEF < 45%
- •Complete left bundle branch block
- •Obligate use of a cardiac pacemaker
- •Congenital long QT syndrome
- •History or presence of ventricular tachyarrhythmia
- •Presence of unstable atrial fibrillation .
- •Clinically significant resting bradycardia
- •Uncontrolled hypertension
- •QTc > 480 msec on screening ECG
- •Right bundle branch block + left anterior hemiblock
- •Angina pectoris ≤ 3 months prior to starting study drug
- •Acute Myocardial Infarction ≤ 3 months prior to starting study drug
- •Other clinically significant heart disease
- •Uncontrolled infection
- •Subjects who did not tolerate previous imatinib treatment.
- •Diabetes mellitus with signs of clinically significant peripheral vascular disease
- •Previous pericarditis; clinically significant pleural effusion in the previous 12 months or current ascites requiring two or more interventions/month
- •Known pre-existing clinically significant disorder of the hypothalamic-pituitary axis, adrenal or thyroid glands
- •Prior acute or chronic pancreatitis of any etiology
- •Malabsorption syndrome or uncontrolled gastrointestinal toxicities with toxicity greater than NCI CTCAE grade 2
- •Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for this study
- •Treatment with any of the medications that have a potential risk of prolonging the QT interval or inducing Torsades de Points and the treatment cannot be discontinued or switched to a different medication prior to starting study drug
- •Use of ketoconazole, erythromycin, carbamazepine, phenobarbital, rifampin, phenytoin and quinidine 2 weeks prior baseline
- •Major surgery ≤ 28 days prior to starting study drug or who have not recovered from side effects of such therapy
- •Known diagnosis of HIV infection
- •History of another primary malignancy that is currently clinically significant or currently requires active intervention
- •Patients with brain metastases as assessed by radiologic imaging due to symptoms clinically suspected of brain metastases
- •Alcohol or substance abuse disorder
研究组 & 干预措施
Dovitinib plus Imatinib
Experimental
Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule
干预措施: dovitinib plus imatinib (Drug)
结局指标
主要结局
Maximal tolerated dose and recommended dose
时间窗: 3 years
Initially three patients will be treated at each dose level. If one out of three patients experiences a DLT, three additional patients will be entered at that dose level. Dose escalation will be continued until DLTs are experienced in two or more out of six patients (more than 33% of patient cohort), which will be defined as the MTD.If more than 33% of patients experience a DLT in a dose level, one doe level below will be the RD
次要结局
- Disease control rate(3 years)
- Number of Participants with Adverse Events as a Measure of Safety(3 years)
- optionally, correlation of efficacy with potential biomarkers(3 years)
- Optionally, activation of FGFR signaling will be analyzed using the reverse phase protein microarray and/or immunohistochemistry including but not limited to pFRS2 and pFGFR in archival tissues and/or newly obtained tissues at baseline(3 years)
- Progression-free survival(3 years)
- next generation sequencing will be performed in newly obtained tissues at baseline to find out new genetic changes after failure of previous standard TKIs(3 years)
- Overall survival (OS)(3 years)
- Imatinib and dovitinib plasma concentrations vs time profile, and basic pharmacokinetics parameters(3 years)
- Overall response rate(3 years)
研究者
Yoon-Koo Kang
Professor
Asan Medical Center
相似试验
终止
2 期
Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)Prostate CancerNCT01994590M.D. Anderson Cancer Center4
已完成
1 期
Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary CancersAdenocarcinoma of the PancreasStage III Pancreatic CancerStage IV Pancreatic CancerUnspecified Adult Solid Tumor, Protocol SpecificNCT01497392Roswell Park Cancer Institute26
招募中
2 期
Avutometinib and Defactinib in Diffuse Gastric CancerGastric CancerStomach CancerNCT06487221Ryan H. Moy, MD, PhD27
已完成
1 期
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone MetastasisBone MetastasesBreast CancerNCT00566618M.D. Anderson Cancer Center31
撤回
1 期
Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic PhaseMyeloid Leukemia, Chronic, Chronic-PhaseNCT00324077Bristol-Myers Squibb